Drug Profile
UCART 123
Alternative Names: Anti-CD123 CAR-T Cells-Cellectis; UCART-123; UCART-123v1.2Latest Information Update: 15 Dec 2022
Price :
$50
*
At a glance
- Originator Cellectis
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acute myeloid leukaemia
- No development reported Blastic plasmacytoid dendritic cell neoplasm
Most Recent Events
- 13 Dec 2022 Updated efficacy, adverse events and pharmacokinetics data from the phase I AMELI-01 trial in Acute myeloid leukemia presented at the 64th Annual Meeting of the American Society of Hematology (ASH-Hem-2022)
- 05 Dec 2022 UCART 123 is still in phase I AMELI-01 trial for Acute myeloid leukemia (Second line therapy or greater) in USA (IV, Infusion) (NCT03190278)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)